(6S)-5-Azaspiro[2.4]heptane-6-carboxylic acid is a non-proteinogenic amino acid characterized by a unique spirocyclic structure, which incorporates a cyclopropane ring fused to a pyrrolidine ring. This constrained, rigid scaffold is of significant interest in medicinal chemistry for its ability to influence the conformational properties of peptides and small molecules. This compound serves as a key chiral building block and intermediate in the synthesis of pharmaceutical agents. Its primary application is in the development of novel drugs targeting the central nervous system (CNS). Specifically, it is a crucial precursor in the synthesis of besifoxacin, a fourth-generation fluoroquinolone antibiotic, and has been investigated in the research and development of other therapeutic candidates, including potential treatments for cognitive disorders. The spirocyclic structure imparts metabolic stability and can enhance binding affinity to biological targets by pre-organizing the molecule into a bioactive conformation. As a specialty amino acid derivative, it is utilized in the design of peptidomimetics and bioactive compounds where modifying backbone geometry is desired to improve pharmacokinetic or pharmacodynamic properties.